Naproxcinod

Generic Name
Naproxcinod
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H21NO6
CAS Number
163133-43-5
Unique Ingredient Identifier
V24GR4LI3I
Indication

Investigated for use/treatment in pain (acute or chronic), inflammatory disorders (unspecified), osteoarthritis, and arthritis and arthritic pain.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide

First Posted Date
2009-05-28
Last Posted Date
2011-06-17
Lead Sponsor
NicOx
Target Recruit Count
31
Registration Number
NCT00909519

A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function

Phase 1
Completed
Conditions
Renal Failure
Interventions
Drug: naproxcinod
First Posted Date
2008-05-08
Last Posted Date
2009-01-28
Lead Sponsor
NicOx
Target Recruit Count
32
Registration Number
NCT00674856

A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects

Phase 1
Completed
Conditions
Liver Disease
Interventions
Drug: naproxcinod
First Posted Date
2008-02-22
Last Posted Date
2011-06-17
Lead Sponsor
NicOx
Target Recruit Count
24
Registration Number
NCT00621881

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip

First Posted Date
2007-10-10
Last Posted Date
2009-02-20
Lead Sponsor
NicOx
Target Recruit Count
800
Registration Number
NCT00541489

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

Phase 2
Terminated
Conditions
Prostatic Neoplasms
Prostate Cancer
First Posted Date
2006-10-03
Last Posted Date
2013-01-28
Lead Sponsor
Stanford University
Target Recruit Count
20
Registration Number
NCT00383487
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy